Matthew Gline

Matthew Gline

Chief Executive OfficeratRoivant Sciences· In proxies 2020–2024

Pay in FY2024+22,021% from the year before · Roivant Sciences stock +42.8% the same year

Matthew Gline was paid $163.3M in FY2024 (Mar), up 22,021%. Roivant Sciences stock rose 42.8% that year.

Pay$100 in the stock at the end of FY22 → $213
Pay is from the Summary Compensation Table of each Roivant Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Roivant SciencesPublic company · 6 yr
    • Chief Executive Officer2020 – Present · 6 yrStock in role +356%
  2. Arbutus Biopharma CorporationPublic company
    • Director? – PresentNo stock prices for these years
  3. DatavantPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?